{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:31:52Z","timestamp":1791412312952,"version":"4.3.3"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1331,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1111\/j.1365-2133.2011.10663.x","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T14:21:33Z","timestamp":1317651693000},"page":"405-412","source":"Crossref","is-referenced-by-count":87,"title":["Low-dose rituximab is effective in pemphigus"],"prefix":"10.1093","volume":"166","author":[{"given":"B.","family":"Horv\u00e1th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.H.","family":"Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Jonkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,9]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB1|cit1","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","volume":"1","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000100876","article-title":"Rituximab (anti-CD20 monoclonal antibody) - ultimate or first choice in pemphigus?","volume":"214","author":"Hertl","year":"2007","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1529-8019.2007.00141.x","article-title":"Off-label uses of rituximab in dermatology","volume":"20","author":"Carr","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB4|cit4","first-page":"1763","article-title":"Clinical status and optimal use of rituximab for B-cell lymphomas","volume":"12","author":"McLaughlin","year":"1998","journal-title":"Oncology"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2133.2011.10663.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/ard.2009.123885","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009","volume":"69","author":"Furst","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB7|cit7","first-page":"224","article-title":"Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus - an update","volume":"15","author":"Arin","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB8|cit8","first-page":"269","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus","volume":"137","author":"Borradori","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB10|cit10","first-page":"564","article-title":"Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus","volume":"2","author":"Schadlow","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB20|cit20","first-page":"116","article-title":"Rituximab voor de behandeling van refractaire auto-immuun-blaarziekten","volume":"19","author":"van Duinen","year":"2009","journal-title":"Ned Tijdsch Derm Ven"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-4632.2008.03423.x","article-title":"Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris","volume":"47","author":"Faurschou","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaad.2004.06.007","article-title":"Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)","volume":"51","author":"Morrison","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000287254","article-title":"Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature","volume":"221","author":"Fuertes","year":"2010","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00105-008-1682-0","article-title":"Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases","volume":"60","author":"Alter","year":"2009","journal-title":"Hautarzt"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2133.2003.05580.x","article-title":"Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab","volume":"149","author":"Goebeler","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","article-title":"Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins","volume":"158","author":"Shimanovich","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","article-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients","volume":"156","author":"Goh","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB32|cit32","first-page":"266","article-title":"Delayed response of oral pemphigus vulgaris to rituximab treatment","volume":"16","author":"Niedermeier","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2133.2007.08189.x","article-title":"Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases","volume":"157","author":"Rios-Fernandez","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"321950","DOI":"10.1155\/2010\/321950","article-title":"Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris","volume":"2010","author":"Muller","year":"2010","journal-title":"Dermatol Res Pract"},{"key":"10.1111\/j.1365-2133.2011.10663.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10663.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10663.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:53:48Z","timestamp":1676364828000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/166\/2\/405\/6613812"}},"subtitle":["Low-dose rituximab in pemphigus"],"short-title":[],"issued":{"date-parts":[[2012,1,9]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10663.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13988964.15775072","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.13988964.15445066","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,9]]}}}